Ataraxis launches causal multimodal AI predicting chemo benefit, raises $20.4M Series A
multiply_matrix · x · 2026-09-14
Ataraxis released CTX, a causal multimodal AI model (with three preprints) that predicts, from a routine pathology slide plus clinical variables, the five-year recurrence-free survival gain a specific patient gets from adding chemotherapy—separating recurrence risk from treatment benefit and generalizing zero-shot from breast cancer to multiple solid tumors. The company previously raised a $20.4M Series A to accelerate clinical deployment.
More from Venture
- Time Warner mocked Netflix in 2010; now Netflix wants to buy WBD — the triumph of Geek Doctrine — amcafee · 2026-09-15
- The hidden cost of failed agent runs: one task may burn twice the credits on Codex — ToneAromatic178 · 2026-09-15
- Whop adds Alipay and WeChat Pay for China buyers, sellers paid in USD — eptwts · 2026-09-15
- Two kinds of AI companies: levered bottleneck winners vs. healthy long-run balance sheets — RihardJarc · 2026-09-15
- Robotics AI evaluator Robocurve raises $10M seed with YC participation — ycombinator · 2026-09-15
- Cybersecurity stocks surge in unison: CRWD +15%, ZS +16%, PANW and RBRK +14% — matt_slotnick · 2026-09-15